Full-Time

Senior Director

Clinical Development

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$285k - $315k/yr

+ Bonus

Philadelphia, PA, USA + 2 more

More locations: Malvern, PA, USA | Bridgewater, NJ, USA

Hybrid

Hybrid work arrangement; up to 20% travel.

MD

Category
Biology & Biotech (1)
Required Skills
Data Analysis
Google Cloud Platform

Get referred to Mallinckrodt

See people who can refer or advise you

Requirements
  • A board-licensed Doctor of Medicine or equivalent foreign qualification in Immunology is required.
  • A minimum of 8-10 years of Clinical Development experience in Immunology or Autoimmunity is required.
  • Previous experience designing and developing Phase 1-4 protocols is required.
  • The candidate must be able to analyze and interpret data, assess clinical relevance, and present or report findings, including ISS, ISE, and competitor data.
  • Experience working on a matrix cross-functional clinical team is required.
  • The candidate must be able to manage multiple and diverse projects concurrently.
  • The candidate must be able to develop relationships and generate collaborations.
  • Strong analytical skills, strategic thinking, planning, implementation, and a proven negotiating track record are required.
  • Strong medical and scientific writing skills, together with appropriate clinical, scientific, and medical knowledge, are required to author, design, and implement clinical protocols and other study documents.
  • Working knowledge of statistics, data analysis, and data interpretation is required.
  • Experience with clinical trial operations and related activities, including investigator meetings, DSMBs, and GCP/ICH, is required.
  • Excellent written and oral communication skills are required.
  • Organizational and cross-functional collaboration skills are required.
  • Proficiency in Microsoft Office Suite is required.
  • The candidate must be able to work with colleagues at all levels of responsibility and authority.
  • The candidate must be able to work on multiple projects with aggressive timelines.
  • The candidate must be action-oriented, flexible, and able to adapt to changes in priorities, projects, and daily activities.
  • Strong presentation skills are required.
  • Strong MSP skills are required.
  • The candidate must be able to travel up to 20%.
Responsibilities
  • Provide expert clinical advice across Phase II-IV clinical research and serve as the responsible clinical lead from the Clinical Development function.
  • Oversee and manage the clinical development execution aspects of clinical development programs.
  • Oversee multiple clinical study programs or therapeutic focus areas and establish a resource model using external and internal resources as indicated.
  • Lead the design and development of clinical studies and write required clinical documents in collaboration with Medical Writing, including protocol concept forms, clinical study synopses, clinical study protocols, and investigator brochures.
  • Ensure on-time achievement of study and program milestones in alignment with program team strategic imperatives.
  • Serve as the clinical point of contact between internal teams and external groups, including clinical operations, vendors, investigators, regulatory authorities, medical affairs, key opinion leaders, and advisory boards.
  • Act as the lead clinical representative on project teams.
  • Contribute to clinical development strategy across multiple indications.
  • Develop, review, guide, and approve protocols, amendments, informed consent forms, and clinical sections of other documents.
  • Oversee safety monitoring of ongoing clinical studies under the role’s leadership with appropriate support.
  • Lead engagements with thought leaders within the respective therapeutic area or indication.
  • Track Clinical Development deliverables across clinical studies and projects with Program Management.
  • Identify, contract, and engage subject matter experts and thought leaders for advisory board meetings and consultancy activities.
  • Oversee regular maintenance and updates of Clinical Development project folders and drives.
  • Review informed consent forms and ensure alignment with related safety sections of study protocols.
  • Develop, review, or approve clinical, safety, and monitoring case report form pages.
  • Collaborate in study team meetings, data monitoring committee meetings, and steering committees as necessary.
  • Identify additional opportunities within the R&D portfolio, propose indications and study design approaches for proof of concept, and help identify and evaluate in-licensing or merger and acquisition opportunities that expand the platform portfolio.
  • Review, guide, and finalize study documents, including protocol synopses, protocols, protocol amendments, and administrative change letters.
  • Ensure Clinical Development contributions to trial-related documents, including investigator brochures, informed consent forms, case report forms, case report form completion guidelines, study execution and monitoring plans, clinical data review plans, clinical database specifications, statistical analysis plans, data management plans, safety management plans, medical monitoring plans, and clinical study reports.
  • Ensure regular and ad hoc data reviews and interpretation and prepare summaries and documentation of these reviews for leadership.
  • Ensure timely development of program-level documents, including abstracts, manuscripts, presentations, and other internal and external documents and communications.
  • Prepare abstracts, manuscripts, and presentations for external meetings and author clinical sections of regulatory documents, including clinical study reports, investigator brochures, investigational new drug sections, clinical trial application sections, integrated summary of safety sections, integrated summary of efficacy sections, and clinical expert reports.
  • Develop operational strategies for clinical research studies and development programs in collaboration with Development Operations, including principal investigator selection, contract research organization selection, budgets, and timelines.
  • Participate in vendor selection, specification development, and vendor management or oversight as needed.
  • Ensure development of study-specific training materials for study teams, investigational sites, and vendors.
  • Participate and present at investigator meetings or similar meetings.
  • Lead responses to scientific and data-related queries.
  • Collaborate with statisticians on data review and interpretation.
  • Act as the primary medical monitor, with support as required, to identify trial-related safety trends and generate reports interpreting, analyzing, and summarizing data and trends.
  • Develop or review narratives for adverse events, serious adverse events, and adverse events of special interest.
  • Collaborate with statisticians to identify trial-related efficacy trends and generate reports interpreting, analyzing, and summarizing data and trends.
Desired Qualifications
  • Previous project management or clinical operations experience is desirable.
  • Therapeutic area experience is preferred, demonstrated with two or more years of relevant experience.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 12, 2026 guidance reaffirmed $1.94 billion to $2.00 billion sales.
  • First-quarter 2026 sales reached $468 million, up $261 million year over year.
  • Keenova booked $23 million merger synergies and targets $150 million annual run-rate savings.

What critics are saying

  • Opioid litigation still shadows the business after 2023 and 2025 bankruptcies.
  • Integration failure or synergy misses would damage 2026 EBITDA guidance and NYSE listing plans.
  • Another leverage shock or adverse court ruling could force a third restructuring.

What makes Mallinckrodt unique

  • Acthar Gel and XIAFLEX anchor Keenova's branded specialty franchise in 2026.
  • July 31, 2025 Endo merger created a larger U.S.-focused therapeutics platform.
  • Christiana Stamoulis joined September 22, 2025 to drive M&A and corporate development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

StockTitan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.